Limerston Capital Acquires Concept Life Sciences from Spectris plc

Limerston Capital‑backed Concept Life Sciences Acquires Charnwood Discovery

November 8, 2024

Healthcare Services

Limerston Capital‑backed Concept Life Sciences (CLS) has acquired Charnwood Discovery, a UK-based drug discovery contract research provider headquartered in Loughborough. The add-on strengthens CLS's integrated drug discovery, chemistry, biology and ADME/DMPK capabilities and expands its ability to accelerate drug candidates to clinic while providing customers access to CLS's broader translational biology and GMP manufacturing services.

Limerston Capital Acquires CyberCrowd to Build Cybersecurity Platform

May 27, 2024

Cybersecurity

London-based private equity firm Limerston Capital has acquired UK-based cyber security services specialist CyberCrowd as the first step in building a new cybersecurity platform alongside assets from an earlier acquisition. The combined group will offer digital forensics, e-Discovery, a proprietary forensic case management tool, a 24/7 UK-based SOC, incident response, and scaled consultancy and penetration testing services to public and private sector clients.

Pace Analytical Life Sciences Acquires Bio-Concept Laboratories

December 8, 2020

Pharmaceuticals

Pace Analytical Life Sciences, a subsidiary of Pace Analytical Services, acquired Bio-Concept Laboratories, a Salem, New Hampshire-based pharmaceutical CDMO specializing in sterile aqueous formulation development and fill–finish manufacturing. The deal expands Pace’s sterile materials and ophthalmic manufacturing capabilities to better support clinical trial and drug development programs and strengthens its New England CDMO footprint.

Limerston Capital Acquires Source BioScience's Stability Storage Business to Form Astoriom

January 15, 2023

Healthcare Services

Limerston Capital has acquired Source BioScience's Stability Storage business (renamed Astoriom) from Source BioScience. The UK-headquartered biorepository specialist, based in Rochdale with 33 employees, will be developed as a platform for buy-and-build expansion into the US and European pharmaceutical and biologics markets.

EQT Acquires LSP (Life Sciences Partners)

November 10, 2021

Financial Services

EQT AB has acquired LSP (Life Sciences Partners), a leading European life-sciences venture capital firm, in a transaction that creates a new EQT Life Sciences business line. The deal values the upfront consideration at EUR 450 million (25% cash / 75% EQT shares) with a EUR 25 million earn‑out paid on meeting fundraising targets (total consideration EUR 475 million at close); LSP's 34-person team and partners join EQT to strengthen its healthcare investing capabilities.

L2P Research Acquires METIS Research Laboratories

February 28, 2020

Biotechnology

L2P Research, LLC has acquired METIS Research Laboratories, a Ronkonkoma, New York-based preclinical CRO that provides radiotracer, radioligand binding, ADME/PK and QWBA services. The acquisition adds a GLP-compliant 5,000 sq. ft. facility and expands L2P's preclinical capabilities for pharma, biotech and academic customers.